Currently, the classical methods employed in the treatment of PCa include androgen deprivation therapy using CYP17A1 inhibitors and/or blocking AR binding to its ligand using AR antagonists [66,67] (Figure 12). The gene discussed is CYP17A1; the disease is posterior cortical atrophy.